Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda And Pfizer Sign A Co-Promotion Deal To Market Actos In China

This article was originally published in PharmAsia News

Executive Summary

Facing a looming patent cliff, Japan's Takeda made good on a pledge to dive into emerging markets by signing a co-promotion deal with Pfizer to market its type 2 Actos diabetes drug in China

You may also be interested in...



Takeda, Sanofi Team Up To Explore DPP-4 Market In China

Takeda will partner with Sanofi to co-promote its DPP-4 inhibitor Nesina, which is expected to be approved in China this year.

Takeda, Sanofi Team Up To Explore DPP-4 Market In China

Takeda will partner with Sanofi to co-promote its DPP-4 inhibitor Nesina, which is expected to be approved in China this year.

Takeda Buys Out Chinese Venture, Gains Flexibility In Decision-making For Commercial Expansion

TOKYO - Takeda currently posts only limited sales in China, but the company hopes that the full acquisition of its Chinese joint venture Tianjin Takeda will give the company more flexibility and speed in making business decisions to expand its presence in China

Related Content

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel